Literature DB >> 27232063

Parkinson's disease and colorectal cancer risk-A nested case control study.

Ben Boursi1, Ronac Mamtani2, Kevin Haynes3, Yu-Xiao Yang4.   

Abstract

BACKGROUND: A pro-inflammatory gut microbiota was described in both Parkinson's disease and colorectal cancer (CRC) and recently α-synuclein was demonstrated in the enteric nervous system. We sought to evaluate the association between Parkinson's disease and CRC.
METHODS: We conducted a nested case-control study using a large primary-care database. Cases were defined as all individuals with CRC. Up to 4 controls were matched with each case based on age, sex, practice-site and duration of follow-up. The primary exposure of interest was diagnosis of Parkinson's disease prior to CRC as well as disease duration, and Parkinson's specific therapies. The primary analysis was a conditional logistic-regression to estimate odds ratios (ORs) and 95% confidence interval (95%CI).
RESULTS: The study included 22,093 CRC cases and 85,833 matched controls. Past medical history of Parkinson's disease >1 year before index-date was associated with lower CRC risk (OR 0.74, 95%CI 0.59-0.94). The inverse association was more prominent among females compared to males (0.64, 95%CI 0.42-0.96 and 0.8, 95%CI 0.60-1.07, respectively). While patients who received no therapy or therapy with dopamine agonists had a non-significant decrease in cancer risk, patients who were treated with dopamine had a non-significant elevated cancer risk.
CONCLUSION: Parkinson's disease is inversely associated with CRC risk.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Age; Colorectal cancer; Dopamine; Microbiota; Parkinson’s disease; Risk

Mesh:

Year:  2016        PMID: 27232063      PMCID: PMC4963291          DOI: 10.1016/j.canep.2016.05.007

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  50 in total

1.  Differential risks of cancer types in people with Parkinson's disease: a national record-linkage study.

Authors:  Eugene Liat Hui Ong; Raph Goldacre; Michael Goldacre
Journal:  Eur J Cancer       Date:  2014-07-24       Impact factor: 9.162

2.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.

Authors:  James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-04       Impact factor: 2.890

3.  Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses.

Authors:  K Wakabayashi; H Takahashi; S Takeda; E Ohama; F Ikuta
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 4.  Gastrointestinal dysfunction in Parkinson's disease.

Authors:  Alfonso Fasano; Naomi P Visanji; Louis W C Liu; Antony E Lang; Ronald F Pfeiffer
Journal:  Lancet Neurol       Date:  2015-06       Impact factor: 44.182

5.  Comorbid cancer in Parkinson's disease.

Authors:  Raymond Y Lo; Caroline M Tanner; Stephen K Van Den Eeden; Kathleen B Albers; Amethyst D Leimpeter; Lorene M Nelson
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338

Review 6.  Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms.

Authors:  Maria C Rodriguez-Oroz; Marjan Jahanshahi; Paul Krack; Irene Litvan; Raúl Macias; Erwan Bezard; José A Obeso
Journal:  Lancet Neurol       Date:  2009-12       Impact factor: 44.182

7.  Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease.

Authors:  A Rostami-Hodjegan; M S Lennard; H F Woods; G T Tucker
Journal:  Pharmacogenetics       Date:  1998-06

8.  Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease.

Authors:  Andrea Gold; Zorbey T Turkalp; David G Munoz
Journal:  Mov Disord       Date:  2013-01-29       Impact factor: 10.338

9.  The importance of defining periods of complete mortality reporting for research using automated data from primary care.

Authors:  Andrew Maguire; Betina T Blak; Mary Thompson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-01       Impact factor: 2.890

10.  A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease.

Authors:  Jane A Driver; Giancarlo Logroscino; Julie E Buring; J Michael Gaziano; Tobias Kurth
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  6 in total

Review 1.  Mind-altering with the gut: Modulation of the gut-brain axis with probiotics.

Authors:  Namhee Kim; Misun Yun; Young Joon Oh; Hak-Jong Choi
Journal:  J Microbiol       Date:  2018-02-28       Impact factor: 3.422

2.  An edge-based statistical analysis of long non-coding RNA expression profiles reveals a negative association between Parkinson's disease and colon cancer.

Authors:  Suyan Tian; Mingyue Zhang; Zhiming Ma
Journal:  BMC Med Genomics       Date:  2021-02-02       Impact factor: 3.063

3.  Knockdown of Parkinson's disease-related gene ATP13A2 reduces tumorigenesis via blocking autophagic flux in colon cancer.

Authors:  Qian Chen; Li Zhong; Chao Zhou; Yan Feng; Quan-Xing Liu; Dong Zhou; Xiao Lu; Guang-Sheng Du; Dan Jian; Hao Luo; Dong Wang; Hong Zheng; Yuan Qiu
Journal:  Cell Biosci       Date:  2020-12-11       Impact factor: 7.133

4.  Patients with Parkinson's disease predict a lower incidence of colorectal cancer.

Authors:  Hongsheng Fang; Yunlan Du; Shuting Pan; Ming Zhong; Jiayin Tang
Journal:  BMC Geriatr       Date:  2021-10-18       Impact factor: 3.921

5.  Parkinson's disease and cancer: a systematic review and meta-analysis on the influence of lifestyle habits, genetic variants, and gender.

Authors:  Joon Yan Selene Lee; Jing Han Ng; Seyed Ehsan Saffari; Eng-King Tan
Journal:  Aging (Albany NY)       Date:  2022-03-05       Impact factor: 5.682

6.  Parkinson's disease and cancer: a systematic review and meta-analysis of over 17 million participants.

Authors:  Xinyuan Zhang; David Guarin; Niyaz Mohammadzadehhonarvar; Xiqun Chen; Xiang Gao
Journal:  BMJ Open       Date:  2021-07-02       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.